


# EU Initiatives in the field of Neurodegenerative Diseases



# European Commission in research



## Shaping and implementing research policies

- proposes and implements research policies such as the European Research Area, the Europe 2020 strategy and the **Innovation Union**



## Funding research and innovation


- Manages the 7th Framework Programme for Research & Technological Development – **FP7**
- FP7 supports research done by a wide range of participants
- Aims at strengthening the S+T base, increasing the competitiveness of industry and improving lives of citizens





# FP7: 2007 – 2013

Total FP7 budget: € 54,582 billion



\*of which Health €6.1 billion



## What do we want:

- Improving health of European citizens
- Increasing competitiveness of European health-related industries and businesses
- Addressing global health issues
- Supporting the aims of Europe 2020: the 'Innovation Union'
  - Collaborative research: **FP7 projects**
  - Coordinating national research programmes: **ERA-Nets, JPND**
  - International Cooperation Activities: Programme-Level Cooperation with non-EU countries




# FP7 Health - brain research

## What did we do?

- 92 collaborative projects **on the brain and its diseases** supported
- €465 million invested so far on brain diseases
- Of these, €277 million (59%) devoted to research on neurological diseases.
- €180 million = FP7 Health funding going to neurodegenerative diseases (39% of total funding)
- Additional €60 million are expected to be allocated to neurodegenerative disease research as outcome of the 2011 Health call.



# Neurodegenerative Diseases in FP7



# Neurodegenerative diseases research - examples

**MEMOSAD:** aims at defining the molecular mechanisms of Abeta- and Tau-induced synaptotoxicity and at developing disease-modifying therapeutics for the prevention of memory loss in Alzheimer disease

€3 million, 10 partners, 6 EU countries

**MEMSTICK:** investigates the role of novel synaptic cell adhesion molecules (CAMs) in memory loss, and the therapeutic value of targeting these CAMs to restore memory function

€3 million, 7 partners, 6 countries



# the ERA-NETs - Co-ordination of national research activities

**NEURON:** ERA-NET linking European national and regional research funding programmes in the field of disease-related neuroscience

PARTNERS: 15 Funding bodies from 12 Countries

**4 years**

**ERA-AGE:** European Research Area in Ageing

Partners: 12 Funding bodies from 12 Countries

**5 years**





# Joint Programming of Research Activities in the field of Neurodegenerative Diseases



# JOINT PROGRAMMING (Definition)

*Commission Communication on Joint Programming in July 2008*

- ◆ **Member States engaging**
  - ◆ voluntarily and on a variable geometry basis in the definition, development and implementation of common strategic research agendas based on a common vision on how to address major societal challenges.
  
- ◆ **It may involve collaboration between existing national programmes or the setting up of entirely new ones.**
  
- ◆ **It entails putting resources together,**
  - ◆ selecting or developing the most appropriate instrument(s), and
  - ◆ collectively monitoring and reviewing progress.



## Joint Programming Initiative on “Neurodegenerative Diseases, in particular Alzheimer” (JPND)

- Launched in July 2008
- Council Conclusions of 3 December 2009: adopted the JPND



# Why the focus on neurodegenerative diseases, Alzheimer's disease?

A global challenge:



7.3 million Europeans suffer from Alzheimer's disease and other forms of dementia

The total cost of dementia in Europe in 2005 was in the order of € 55 billion

And it will get worse:



Over 11 million Europeans will suffer from Alzheimer's disease and other forms of dementia by 2040



## State-of-play of the JPND

- Led by France (INSERM): Prof. Philippe AMOUYEL is the Chair of the Management Board
- Addresses basic science, clinical research and healthcare research
- 23 participating countries (all represented at the Management Board)
- Work with an Executive Board and a Scientific Advisory Board (15 experts)

[www.neurodegenerationresearch.eu](http://www.neurodegenerationresearch.eu)



## JPND current activities

- Mapping exercise has started (contribution of all member countries requested)
- 3 workshops planned (March 2011): basic, clinical and healthcare
- Basis for the Strategic Research Agenda to be completed and approved in 2011



## JPND pilot call

- Discussion on the first pilot call to be launched by the JPND (outside the Strategic Research Agenda)
- Focus on standardization/harmonization of biomarkers in neurodegenerative diseases (*indicative*)
- Potential participation: at least 10 countries, € 6-8 million (*indicative*)



## JPND indicative timelines

- 2011
  - ▶ Launch of Pilot Call
  - ▶ Strategic Research Agenda completed
  
- 2012
  - ▶ Pilot project started
  - ▶ Calls from Strategic Research Agenda
  
- 2013
  - ▶ New projects started







**Thank you for your attention!**

